Martin MacKay, EVP & Global Head of R&D at ALEXION PHARMACEUTICALS INC (ALXN), sold 25,000 shares at $167.40 ($4.2M) on 2014-06-12, disclosed to the SEC on 2014-06-13.
Open-market sale of $4.2M ALXN by EVP & Global Head of R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $165.88 | 5,058 | $839K | 20.2% |
| 2 | $166.35 | 15,949 | $2.7M | 63.8% |
| 3 | $167.40 | 3,993 | $668K | 16.1% |
| Total | $166.42 avg | 25,000 | $4.2M | 100% |
| Filing → |
| ALXN | SELL | 2017-02-10 | $28K | — | Filing → |
| ALXN | SELL | 2017-02-08 | $684K | — | Filing → |
| ALXN | SELL | 2016-05-18 | $1.1M | — | Filing → |